Beranda › Kanker Kandung Kemih › New York › Syracuse
Uji klinis Kanker Kandung Kemih di Syracuse, NY
4 studi untuk Kanker Kandung Kemih mencari peserta di lokasi sekitar Syracuse (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Menerima pesertaFase 1
- Upstate Specialty Services at Harrison Center, Syracuse
- SUNY Upstate Medical University, Syracuse
- SUNY Upstate Medical University-Community Campus, Syracuse
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Menerima pesertaFase 2
- SUNY Upstate, Syracuse
- Associated Medical Professionals of NY, PLLC (US Urology Partners), Syracuse
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Menerima pesertaFase 2
- Associated Medical Professionals of NY, PLLC, Syracuse
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Menerima pesertaFase 1/2
- Associated Medical Professionals of NY,, Syracuse
Uji klinis Kanker Kandung Kemih di kota lain
- New York City, NY35 studi
- Nashville, TN31 studi
- Houston, TX31 studi
- Dallas, TX27 studi
- Boston, MA26 studi
- Washington, DC26 studi
- Los Angeles, CA24 studi
- Baltimore, MD24 studi
- St. Louis, MO22 studi
- Philadelphia, PA21 studi
- Seattle, WA21 studi
- Edison, NJ21 studi
Studi lain di Syracuse
- Kanker Paru Non-Sel Kecil15 studi
- Kanker (semua jenis)9 studi
- Kanker Prostat9 studi
- Kanker Kandung Kemih Non-Invasif Otot8 studi
- Kanker Endometrium7 studi
- Kanker Ovarium7 studi
- Kanker Paru6 studi
- Obesitas6 studi
- Kanker Kolorektal5 studi
- Diabetes Tipe 25 studi
- Gangguan Suara Bicara5 studi
- Kanker Payudara5 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.